¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"beta thalassaemia"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
¿µ¹® beta human chorionic gonadotropin ÇÑ±Û º£Å¸ »ç¶÷À¶¸ð¼º »ý½Ä»ùÀÚ±ØÈ£¸£¸ó
¼³¸í   
  Å¹ݼ¼Æ÷¿¡¼­ ¸¸µé¾îÁö´Â È£¸£¸ó. ±â´ÉÀº ÀÓ½ÅÀÇ Ãʱ⿡ È²Ã¼(¿ø·¡ ³­ÀÚ¸¦ ½Î°í ÀÖ´ø ¼¼Æ÷µéÀÌ ¹è¶õÀÌ ÀϾ¼­ ³­ÀÚ°¡ ºüÁ®³ª°£ ÈÄ ÁÖ¸Ó´Ï ¸ð¾çÀ» ÀÌ·é °Í. ÀÓ½ÅÃʱ⿡ ÀÓ½ÅÀÇ À¯Áö¿¡ ÇÊ¿äÇѠȣ¸£¸óÀ» »ý¼ºÇÑ´Ù)ÀÇ À¯Áö¿¡ ±â¿©Çϰí, Å¾ÆÀÇ °íȯÁ¶Á÷¿¡¼­ ³²¼ºÈ£¸£¸óÀÌ ºÐºñµÇ´Â °ÍÀ» ÃËÁø½ÃŲ´Ù. ¶Ç À̰ÍÀº ÀÓ½ÅÃʱâÀÇ ÀÓ»êºÎÀÇ ¼Òº¯¿¡¼­ ¸¹Àº ¾çÀÌ °ËÃâµÇ¹Ç·Î À̰ÍÀ» ÀÌ¿ëÇØ¼­ ÀÓ½ÅÀÇ ¿©ºÎ¸¦ ¼Õ½±°Ô Á¶»çÇÒ ¼ö°¡ ÀÖ´Ù.
¿µ¹® beta ray ÇÑ±Û º£Å¸¼±
¼³¸í   
  ¹æ»ç¼º ¿øÀÚÇÙÀÌ ¥âºØ±«ÇÔ¿¡ µû¶ó ¹æÃâµÇ´Â ¹æ»ç¼±. ¿øÀÚ¿¡ Á¤»óº¸´Ù ¸¹°Å³ª ÀûÀº Áß¼ºÀÚ³ª ¾çÀÚ¸¦ °¡Áö°í Àִ °æ¿ì¿¡´Â ¿øÀÚ°¡ ¾ÈÁ¤µÇ±â À§ÇÏ¿© ºØ±«°¡ ¼¼°¡Áö ¹æ¹ýÀ¸·Î »ý±ä´Ù. ÀÌÁß Áß¼ºÀÚ°¡ ÇϳªÀÇ ÀüÀÚ¸¦ ³»°í ¾ç¼ºÀÚ°¡ µÇ´Â º¯È­¸¦ °ÅÄ¡¸é¼­ ³ª¿À´Â ÀüÀÚ¼±ÀÌ´Ù. ±× ½Çü´Â °í¼ÓÀÇ ÀüÀÚ ¶Ç´Â ¾çÀüÀÚÀ̸ç ÃÖ´ë ¿¡³ÊÁö´Â 105-107eV. Åõ°ú·Â ¹× ÀÌ¿ÂÈ­ ÀÛ¿ëÀº ¥á¼±°ú ¥ã¼±ÀÇ Áß°£ Á¤µµÀÌ´Ù.
¿µ¹® beta-blocker ÇÑ±Û º£Å¸Â÷´ÜÁ¦
¼³¸í   
  º£Å¸-¼ö¿ëü(1°ú 2¿¡ °ü°è¾øÀÌ)ÀÇ ±â´ÉÀ» ¾ïÁ¦½Ã۴ ¾à¹°·Î ÀÌ ¼ö¿ëü°¡ ¸Å°³ÇÏ¿© »ý±â´Â ½ÅüÀÇ º¯È­¸¦ ¾ïÁ¦ÇÑ´Ù. PropranololÀÌ ÁÁÀº ¿¹ÀÌ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • beta cell
    º£Å¸¼¼Æ÷
  • beta counting
    º£Å¸°è¼ö
  • beta emitter
    º£Å¸¹æÃâü
  • beta error
    º£Å¸¿À·ù, Á¦2Çü¿À·ù
  • beta hemolysis
    º£Å¸¿ëÇ÷, ¿ÏÀü¿ëÇ÷
  • beta particle
    º£Å¸ÀÔÀÚ
  • beta ray
    º£Å¸¼±
  • beta-adrenergic receptor kinase
    º£Å¸¾Æµå·¹³¯¸°¼ö¿ëüÀλêÈ­È¿¼Ò
  • beta-carotene
    º£Å¸Ä«·Îƾ
  • beta-lactam
    º£Å¸¶ôŽ
  • beta-lactamase
    º£Å¸¶ô޾ÆÁ¦
  • beta-lactamase inhibitors
    º£Å¸¶ô޾ÆÁ¦¾ïÁ¦Á¦
  • pre-beta-lipoprotein
    ÇÁ¸®º£Å¸ÁöÁú´Ü¹éÁú
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • beta-carotene
    º£Å¸Ä«·Îƾ
  • beta cell
    º£Å¸¼¼Æ÷
  • beta hemolysis
    º£Å¸¿ëÇ÷
  • beta ray
    º£Å¸¼±
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • beta cell
    º£Å¸¼¼Æ÷
  • beta counting
    º£Å¸°è¼ö
  • beta emitter
    º£Å¸¹æÃâ±â
  • beta error
    Á¦ÀÌÁ¾¿À·ù
  • beta hemolysis
    º£Å¸¿ëÇ÷, ¿ÏÀü¿ëÇ÷
  • beta particle
    º£Å¸ÀÔÀÚ
  • beta ray
    º£Å¸¼±
  • beta-adrenergic receptor kinase
    º£Å¸¾Æµå·¹³¯¸°¼º¼ö¿ëüÀλêÈ­È¿¼Ò
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • 11-beta-hydroxylase
    11-º£Å¸-¼ö»êÈ­È¿¼Ò, 11-º£Å¸-È÷µå·Ï½Ç¶óÁ¦
  • 3-beta-hydroxysteroid dehydrogenase
    3-º£Å¸-È÷µå·Ï½Ã½ºÅ×·ÎÀ̵å Å»¼ö¼ÒÈ¿¼Ò
  • O-Nitrophenyl-beta-galactoside => ONPG
    O-´ÏÆ®·ÎÆä´Ò-º£Å¸-°¥¶ôÅä½Ãµå
  • acetyl-beta-methylcholine
    ¾Æ¼¼Æ¿-º£Å¸-¸ÞÆ¿Äݸ°
  • alpha/beta (¥á/¥â) ratio
    ¥á/¥â ºñ
  • gamma-delta-beta thalassemia
    °¨¸¶-µ¨Å¸-º£Å¸- ÁöÁßÇØ¼ººóÇ÷
  • hypoglycemia, beta cell tumor
    ÀúÇ÷´ç(Áõ), º£Å¸¼¼Æ÷Á¾
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • beta-ARK : beta-adrenergic receptor kinase
    º£Å¸-¾Æµå·¹³¯¸°(¼º)¼ö¿ëü ÀλêÈ­È¿¼Ò.
  • acetyl-beta-methylcholine
    ¾Æ¼¼Æ¿-º£Å¸-¸ÞÆ¿Äݸ°
  • alpha/beta (¥á/¥â) ratio
    ¥á/¥â ºñ
  • beta (¥â) chain
    º£Å¸»ç½½, º£Å¸¼â
  • beta (¥â) globulin
    º£Å¸±Û·ÎºÒ¸°
  • beta (¥â) hemolysis
    º£Å¸¿ëÇ÷, ¿ÏÀü¿ëÇ÷
  • beta (¥â) lysin
    º£Å¸¿ëÇ÷¼Ò, ¿ÏÀü¿ëÇ÷¼Ò
  • beta (¥â) microglobulin
    º£Å¸¹ÌÅ©·Î±Û·ÎºÒ¸°
  • beta (¥â)-interferon
    º£Å¸ÀÎÅÍÆä·Ð
  • beta (¥â)-lactam
    º£Å¸¶ôŽ
  • beta (¥â)-lactam antibiotic
    º£Å¸¶ôŽ Ç×»ýÁ¦
  • beta (¥â)-lactamase
    º£Å¸¶ôŸ¸¶Á¦, º£Å¸¶ôŽ °¡¼öºÐÇØÈ¿¼Ò
  • beta (¥â)-lactamase inhibitor
    º£Å¸¶ôŸ¸¶Á¦¾ïÁ¦Á¦
  • beta =¥â
    º£Å¸.
  • beta adrenergic receptor
    º£Å¸¾Æµå·¹³¯¸°¼º ¼ö¿ëü(¼ö¿ë±â, °¨¼öü)
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Beta cell [Insulin cell]
    º£Å¸¼¼Æ÷ [Àν´¸°¼¼Æ÷]
    [¿¾ ¿ë¾î] º£Å¸¼¼Æ÷
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • beta
    "º£Å¸, (ÔÒ) ¥â"
  • beta adrenergic blocker
    º£Å¸ ¾Æµå·¹³¯¸°ÀÛµ¿(íÂÔÑ) Â÷´ÜÁ¦(ó´Ó¨ð¥)
  • beta adrenergic receptor
    º£Å¸ ¾Æµå·¹³¯¸° ¼ö¿ëü(áôé»ô÷)
  • beta amylase
    º£Å¸ ¾Æ¹Ð·¹À̽º
  • beta bend
    º£Å¸ ±ÁÀ½
  • beta benzyme
    º£Å¸ º¥ÀÚÀÓ
  • beta blocker
    º£Å¸ Â÷´ÜÁ¦(ó´Ó¨ð¥)
  • beta carotene
    º£Å¸ Ä«·ÎÅÙ
  • beta chain
    º£Å¸ »ç½½
  • beta conformation
    º£Å¸ ÀÔü ÇüÅÂ(í¡ô÷ û¡÷¾)
  • beta decay
    º£Å¸ ºØ±«(ÝÚÎÕ)
  • beta emitter
    º£Å¸ ¹æÃâÀÚ(Û¯õóíº)
  • beta error
    º£Å¸ ¿ÀÂ÷(è¦ó¬)
  • beta fraction
    º£Å¸ ºÐȹ(ÝÂüñ)
  • beta galactosidase
    º£Å¸ °¥¶ôÅä½Ãµ¥À̽º
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • beta
    º£Å¸
  • beta blocker
    º£Å¸Â÷´ÜÁ¦
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
BB bad breath; bed bath; beta blockade, beta blocker; BioBreeding [rat]; blanket bath; blood bank; bloo...
beta [Greek letter beta] an anomer of a carbohydrate; buffer capacity; carbon separated from a carboxyl by one other carbon i...
BG basal ganglion; basic gastrin; Bender Gestalt [test]; beta-galactosidase; beta-glucuronidase; bicolo...
VLAB, VLA-BETA very late activation protein beta
¥â-HCG(hCG) Beta(¥â)-Human Chorionic Gonadotropin; »ç¶÷À¶¸ð¼º¼º¼±ÀÚ±ØÈ£¸£¸ó
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
beta Thal beta thalassaemia
[(123)I]-beta-CIT 123)I]-2-beta-carbomethoxy-3-beta-(4-iodophenyl)-tropane
3 beta-diol alpha-Androstane-3 beta,17 beta-diol
beta-glucan 1----3)-beta-D-glucan
beta-CyD 1/beta-cyclodextrin
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
  • D56.1
    Beta thalassaemia
    º£Å¸ ÁöÁßÇØºóÇ÷
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • beta-aminoisobutyric aciduria ¿äÁß¿¡ º£Å¸-¾Æ¹Ì³ë ¾ÆÀ̼ҴлêÀÌ °úµµ·Î ¹è¼³µÇ´Â °Í. ¾ç¼ºÀÇ À¯Àü¼º ´ë»ç¼º ÀÌ»óÀ¸·Î ÀϾ¸ç ±×¸®°í ƯÁ¤ÇÑ Áúȯ¿¡¼­µµ ³ªÅ¸³­´Ù.

    beta-arrestin

    º£Å¸-¾î·¹½ºÆ¾
  • A beta
    A º£Å¸, A º£Å¸ ½Å°æ ¼¶À¯
    Á¢ÃË, ¾Ð·Â, Áøµ¿ µî ´ëºÎºÐÀÇ Ã˰¢À» Àü´ÞÇÏ´Â ±½Àº À¯¼ö ½Å°æÀÌ´Ù. Á÷°æÀº 13-22§­, ½Å°æ Àü´Þ ¼Óµµ´Â 70-120§½ÀÌ´Ù.
  • A-beta fiber
    A-º£Å¸ ½Å°æ ¼¶À¯
    Á¢ÃË, ¾Ð·Â ÀÚ±ØÀ» Àü´ÞÇÏ´Â À¯¼ö ½Å°æÀÌ´Ù.
  • acetyl-beta-methylcholine
    ¾Æ¼¼Æ¿-º£Å¸-¸ÞÆ¿Äݸ°
  • beta
    ¥â
    hemolysis
  • beta
    º£Å¸
    ±×¸®½º¾î ¾ËÆÄºªÀÇ µÎ ¹øÂ° ¹®Àڷμ­ È­ÇÐ¸í¿¡ À־´Â 2°³ ÀÌ»óÀÇ À̼ºÃ¼ Áß Çϳª¸¦ Ç¥½ÃÇÏ´Â µ¥ »ç¿ëÇÑ´Ù. ¶ÇÇÑ È­ÇÕ¹°¿¡¼­ ġȯ ¿øÀÚ³ª ¿øÀÚ´ÜÀÇ À§Ä¡¸¦ Ç¥½ÃÇÏ´Â µ¥ »ç¿ëµÈ´Ù.
  • beta cell tumor
    º£Å¸ ¼¼Æ÷Á¾
  • beta hemolysis
    º£Å¸ ¿ëÇ÷, º£Å¸Çü ¿ëÇ÷
  • beta ray
    º£Å¸ ¼±
    ¹æ»ç¼± ¹°Áú¿¡¼­ ³ª¿À´Â ÀüÀÚ¼±À¸·Î ±¤¼ÓÀÇ 0.98¹èÀÇ ÃÖ´ë¼Óµµ¸¦ °¡Áø´Ù.
  • beta receptor blocker
    º£Å¸ ¼ö¿ëü Â÷´ÜÁ¦
  • beta test
    º£Å¸ ½ÃÇè
  • beta wave
    º£Å¸ ÆÄ
  • beta-adrenergic blocking agent
    º£Å¸ ¾Æµå·¹³¯¸°¼º Â÷´ÜÁ¦
  • beta-cell tumor
    º£Å¸ ¼¼Æ÷ Á¾¾ç
    µµ¼¼Æ÷ Á¾¾ç Áß °¡Àå ÈçÇÑ Áúº´À¸·Î Àν¶¸° °ú´Ù ºÐºñ°¡ ÀϾ´Ù.
  • beta-endorphin immunoreactivity
    º£Å¸ ¿£µµ¸£ÇÉ ¸é¿ª ¹ÝÀÀ
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
beta thalassaemia <haematology> Thalassaemia due to one of two or more genes that depress (partially or completely) synthesis of beta-globin chains by the chromosome bearing the abnormal gene. Heterozygous state (A2 t.): thalassaemia minor with Hb A2 increased, Hb F normal or variably increased, Hb A normal or slightly reduced. Homozygous state: thalassaemia major with Hb A reduced to very low but variable levels, Hb F very high level.
A disorder characterised by reduced synthesis of the beta chains of haemoglobin. There is retardation of haemoglobin a synthesis in the heterozygous form (thalassaemia minor), which is asymptomatic, while in the homozygous form (thalassaemia major, cooley's anaemia, mediterranean anaemia, erythroblastic anaemia), which can result in severe complications and even death, haemoglobin a synthesis is absent.
(05 Mar 2000)
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
beta-d thalassaemia Thalassaemia due to a gene that depresses synthesis of both beta-and d-globin chains by the chromosome bearing the abnormal gene. Heterozygous state: thalassaemia minor with Hb F comprising 5 to 30% of total haemoglobin but distributed unevenly among cells, Hb A2 reduced or normal. Homozygous state: moderate anaemia with only Hb F present, no Hb A or Hb A2.
Synonym: F thalassaemia.
(05 Mar 2000)
thalassaemia, beta Also known as thalassaemia major.The clinical picture of this important type of anaemia was first described in 1925 by the paediatrician thomas benton cooley. Other names for the disease are cooley's anaemia and mediterranean anaemia. The name thalassaemia was coined by the nobel prise winning pathologist george whipple and the professor of paediatrics wm bradford at u. Of rochester because thalassa in greek means the sea (like the mediterrranean sea) + -aemia means in the blood so thalassaemia means sea in the blood. Thalassaemia is not just one disease. It is a complex contingent of genetic (inherited) disorders all of which involve underproduction of haemoglobin, the indispensable molecule in red blood cells that carries oxygen. The globin part of normal adult haemoglobin is made up of 2 alpha and 2 beta polypeptide chains. In beta thalassaemia, there is a mutation (change) in both beta globin chains leading to underproduction (or absence) of beta chains, underproduction of haemoglobin, and profound anaemia. The gene for beta thalassaemia is relatively frequent in people of mediterranean origin (for example, from italy and greece). Children with this disease inherit one gene for it from each parent. The parents are carriers (heterozygotes) with just one thalassaemia gene, are said to have thalassaemia minor, and are essentially normal. Their children affected with beta thalassaemia seem entirely normal at birth because at birth we still have predominantly foetal haemoglobin which does not contain beta chains. The anaemia surfaces in the first few months after birth and becomes progressively more severe leading to pallor and easy fatiguability, failure to thrive (grow), bouts of fever (due to infections) and diarrhoea. Treatment based on blood transfusions is helpful but not curative. Gene therapy will, it is hoped, be applicable to this disease.
(12 Dec 1998)
A2 thalassaemia Beta thalassaemia, heterozygous state.
(05 Mar 2000)
alpha thalassaemia <haematology> A condition characterised by the reduced synthesis of the alpha chain of haemoglobin due to abnormality in one of two or more genes that code for the synthesis of alpha-globin chains. The severity of this condition can vary from mild anaemia to death, depending on the number of genes deleted.
Heterozygous state: severe type, thalassaemia minor with 5 to 15% of Hb Barts at birth, only traces of Hb Barts in adult; mild type, 1 to 2% of Hb Barts at birth, not detectable in adult.
Homozygous state: severe type, erythroblastosis foetalis and foetal death, only Hb Barts and Hb H present; mild type not clinically defined.
See: haemoglobin H.
(05 Mar 2000)
a thalassaemia intermedia See: haemoglobin H.
(05 Mar 2000)
sickle cell-thalassaemia disease Anaemia, clinically resembling sickle cell anaemia, in which individuals are compound heterozygous for the sickle cell gene and a thalassaemia gene; about 60 to 80% of haemoglobin is Hb S, up to 20% Hb F, and the remainder Hb anaemia.
Synonym: sickle cell-thalassaemia disease.
(05 Mar 2000)
thalassaemia <haematology> A genetic form of anaemia in which there is abnormality of the globin portion of haemoglobin.
Affected individuals cannot synthesise haemoglobin properly, and they produce small, pale, short-lived red blood cells.
Widespread in Mediterranean countries.
Origin: Gr. Haima = blood
(11 Jan 1998)
thalassaemia intermedia A clinical variant of thalassaemia characterised by an intermediate degree of severity. These patients have severe anaemia but usually do not require regular blood transfusions. Intermedia disorders represented a heterogeneous group of genetic disorders and may include cases with homozygous or heterozygous abnormalities in the beta-globin chain gene.
(05 Mar 2000)
thalassaemia major The dire disease also known as beta thalassaemia. The clinical picture of this form of anaemia was first described in 1925 by the paediatrician thomas benton cooley. Other names for the disease are cooley's anaemia and mediterranean anaemia. The term thalassaemia was coined by the nobel prise winning pathologist george whipple and the professor of paediatrics william bradford at u. Of rochester because thalassa in greek means the sea (like the mediterrranean sea) + -aemia means in the blood so thalassaemia means sea in the blood. Thalassaemia is not just one disease. It is a complex contingent of genetic (inherited) disorders all of which involve underproduction of haemoglobin, the indispensable molecule in red blood cells that carries oxygen. The globin part of normal adult haemoglobin is made up of 2 alpha and 2 beta polypeptide chains. In beta thalassaemia, there is a mutation (change) in both beta globin chains leading to underproduction (or absence) of beta chains, underproduction of haemoglobin, and profound anaemia. The gene for beta thalassaemia is relatively frequent in people of mediterranean origin (for example, from italy and greece). Children with this disease inherit one gene for it from each parent (and so are said to be homozygous for beta thalassaemia). The parents are carriers (heterozygotes) with just one thalassaemia gene, are said to have thalassaemia minor, and are essentially normal. Their children affected with beta thalassaemia seem entirely normal at birth (because at birth we still have predominantly foetal haemoglobin which does not contain beta chains) but the anaemia emerges in the first few months of life and becomes progressively more severe leading to pallor and easy fatiguability, failure to thrive (grow), bouts of fever (due to infections) and diarrhoea. Treatment based on blood transfusions is helpful but not curative. Gene therapy will, it is hoped, be applicable to this disease.
(12 Dec 1998)
thalassaemia minor Also called thalassaemia trait, thalassaemia minor is the carrier state for beta thalassaemia. People who are carriers (heterozygotes) have just one thalassaemia gene, are said to have thalassaemia minor, and are essentially normal.
(12 Dec 1998)
F thalassaemia Thalassaemia due to a gene that depresses synthesis of both beta-and d-globin chains by the chromosome bearing the abnormal gene. Heterozygous state: thalassaemia minor with Hb F comprising 5 to 30% of total haemoglobin but distributed unevenly among cells, Hb A2 reduced or normal. Homozygous state: moderate anaemia with only Hb F present, no Hb A or Hb A2.
Synonym: F thalassaemia.
(05 Mar 2000)
Lepore thalassaemia Thalassaemia syndrome due to production of abnormally structured Lepore haemoglobin. Heterozygous state: thalassaemia minor with about 10% of Hb Lepore, Hb F moderately increased, Hb A2 normal. Homozygous state: thalassaemia major with only Hb F and Hb Lepore produced, no Hb A or Hb A2.
(05 Mar 2000)
androst-5-ene-3 beta,17 beta-diol <chemical> An adrenal-derived oestrogenic metabolite of dhea. Evidence exist for its use as an endocrine regulator of immune response.
Pharmacological action: anabolic steroids.
Chemical name: Androst-5-ene-3,17-diol, (3beta,17beta)-
(12 Dec 1998)
beta-1,3-galactosyl-0-glycosyl-glycoprotein beta-1,3-N-acetylglucosaminyltransferase <enzyme> Capable of adding a glcnac residue to g1cnacman(3)g1cnac; from mung bean seedlings
Registry number: EC 2.4.1.146
Synonym: n-acetylglucosaminyltransferase II, gal3-(glcnac6)galnac-mucin (glcnac--gal)3-glcnactransferase
(26 Jun 1999)
beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-acetylglucosaminyl transferase <enzyme> With EC 2.4.1.148 this is called beta6-glcnac-transferase b
Registry number: EC 2.4.1.102
Synonym: gal3-galnac-mucin-6-glcnac transferase, udp-glcnac-gal1-3galnac-r-(glcnac to galnac)-beta1-6glcnac transferase, core 2 glcnac transferase, core 2-n-acetylglucosaminyltransferase, core 2 beta6-gn-t
(26 Jun 1999)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • beta
    º£Å¸
  • Phi Beta Kappa
    ÆÄÀÌ.º£Å¸.Ä«ÆÄŬ·´
  • beta
    º£Å¸(±×¸®½º¾î ¾ËÆÄºªÀÇ µÑ° ÀÚ)
  • beta minus
    2·ùÀÇÇÏ;2·ùº¸´Ù Á» ¸øÇÑ
  • beta particle
    º£Å¸ÀÔÀÚ
  • beta rays
    º£Å¸¼±
  • beta rhythm
    º£Å¸¸®µë(¸ÅÃÊ 10ÀÌ»óÀÇ ³úÆÄÀÇ ¹éµ¿)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á